MedTrace Logo

A Pharmacokinetic And QT Study Of CP-751,871 In Healthy Subjects

NCT00926263 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2013-05-07

Study results available
· View outcomes & findings →

Summary

This study is primarily to evaluate the single dose pharmacokinetics of CP-751,871 and its effect on QT interval prolongation.

Conditions

  • Healthy Volunteers

Interventions

BIOLOGICAL

CP-751,871

single dose, 1-hr IV infusion

BIOLOGICAL

CP-751,871

single dose, 1-hr IV infusion

BIOLOGICAL

CP-751,871, moxifloxacin, saline

Two doses at 20 mg/kg each on two consecutive days, each administered via 1-hr IV infusion

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00926263 on ClinicalTrials.gov